Journals / Turkish Journal of Gastroenterology / 2021 / Cilt: 32 - Sayı: 9

Histological Characteristics of Non-alcoholic Steatohepatitis in NAFLD Patients With Low Degree of Hepatocyte Apoptosis

Pages
758–764
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: The major risk factors for NASH were central obesity, AST, and the PNPLA3 G allele, in NAFLD with low hepatocyte apoptosis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Caspase-cleaved K18 (cK18) may accurately reflect hepatocyte apoptosis in patients with non-alcoholic steatohepatitis (NASH).
📊
Key Findings & Data:However, NASH can also exist within the normal range of cK18.
💡
Conclusion & Impact:Conclusions: The major risk factors for NASH were central obesity, AST, and the PNPLA3 G allele, in NAFLD with low hepatocyte apoptosis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background: Caspase-cleaved K18 (cK18) may accurately reflect hepatocyte apoptosis in patients with non-alcoholic steatohepatitis (NASH). However, NASH can also exist within the normal range of cK18. The aim of this study was to investigate the risk factors and characteristics of NASH within the normal serum levels of cK18. Methods: In the study, 227 histopathologically confirmed non-alcoholic fatty liver disease (NAFLD) patients with normal cK18 levels (≤200 U/L), measured in serum using ELISA kits, were enrolled. The Rs738409 allele, coding patatin-like phospholipase domain-containing protein 3 (PNPLA3), was detected by MALDI-TOF mass spectrometry. Non-alcoholic steatohepatitis was defined as an NAFLD activity score (NAS) ≥5 with each part >0. Results: The prevalence of NASH was 31.7% among NAFLD patients with normal serum cK18 levels. Compared with non-NASH, NASH had a higher possibility of occurrence with central obesity, insulin resistance, and the G allele of PNPLA3. The mean serum levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were higher in NASH patients. Moreover, ALT, AST, TC, LDL-C, central obesity, and the PNPLA3 G allele were risk factors for NASH in NAFLD patients with normal serum cK18 levels, with odds ratios of 1.01 (95% CI: 1.00, 1.02), 1.03 (95% CI: 1.01, 1.05), 1.33 (95% CI: 1.04, 1.68), 1.41 (95% CI: 1.03, 1.92), 2.19 (95% CI: 1.15, 4.18), and 2.48 (95% CI: 1.15, 5.36), respectively; all P < .05. Conclusions: The major risk factors for NASH were central obesity, AST, and the PNPLA3 G allele, in NAFLD with low hepatocyte apoptosis.

🔖

Cite This Article

MA, H., ZHENG, K. I., TANG, L., LI, G., ZHU, P., WANG, X., CHEN, Y., ZHENG, M. (2021). Histological Characteristics of Non-alcoholic Steatohepatitis in NAFLD Patients With Low Degree of Hepatocyte Apoptosis. Turkish Journal of Gastroenterology, Cilt: 32 - Sayı: 9, 758–764. https://ajindex.com/articles/408883

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019
  2. 4(5):389-398. [CrossRef] 2. Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis. 2018
  3. 22(1):133-140. [CrossRef] 3. Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014
  4. 18(1):19-31. [CrossRef] 4. Lu FB, Zheng KI, Rios RS, et al. Global epidemiology of lean nonalcoholic fatty liver disease: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020
  5. 35(12):2041-2050. [CrossRef] 5. Zheng KI, Fan JG, Shi JP, et al. From NAFLD to MAFLD: A “redefining” moment for fatty liver disease. Chin Med J (Engl). 2020
  6. 133(19):2271-2273. [CrossRef] 6. Zheng KI, Eslam M, George J, Zheng MH. When a new definition overhauls perceptions of MAFLD related cirrhosis care. Hepatobiliary Surg Nutr. 2020
  7. 9(6):801-804. [CrossRef] 7. Goldberg D, Ditah IC, Saeian K, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology. 2017
  8. 152(5):1090- 1099.e1. [CrossRef] 8. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016
  9. 64(1):73-84. [CrossRef] 9. Malhi H, Gores GJ. Cellular and molecular mechanisms of liver injury. Gastroenterology. 2008
  10. 134(6):1641-1654. [CrossRef] 10. Lavallard VJ, Bonnafous S, Patouraux S, et al. Serum markers of hepatocyte death and apoptosis are non-invasive biomarkers of severe fibrosis in patients with alcoholic liver disease. PLOS ONE. 2011
  11. 6(3):e17599. [CrossRef] 11. Kobayashi N, Kumada T, Toyoda H, et al. Ability of Cytokeratin-18 fragments and FIB-4 index to diagnose overall and mild fibrosis nonalcoholic steatohepatitis in Japanese nonalcoholic fatty liver disease patients. Dig Dis. 2017
  12. 35(6):521-530. [CrossRef] 12. Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008
  13. 18(11):1430-1437. [CrossRef] 13. Chu PG, Weiss LM. Keratin expression in human tissues and neoplasms. Histopathology. 2002
  14. 40(5):403-439. [CrossRef] 14. Chu PG, Lau SK, Weiss LM. Keratin expression in endocrine organs a